Included here, you will find important documents concerning ICD-O-3. These files, plus the FY2007 Casefinding List, are useful and needed while performing ICD-O-3 casefinding and implementation activities:
FY2007 Casefinding List
Cancer registries and cancer surveillance programs typically describe the reportable neoplasms as any neoplasm with a behavior code (fifth digit in a complete six-digit morphology code) of ‘/2' (in situ) or ‘/3' (invasive). Some registries also collect and report the benign (‘/0') and borderline (‘/1') neoplasms.
The following list is intended to assist in reportable neoplasm casefinding activities that are performed in casefinding sources that use ICD-9-CM* (modified October 2006) codes to codify the diagnoses. Codes and/or terms that have new malignant behavior codes in ICD-O-3 are underlined and the ICD-O-3 code is placed in parentheses following the terms.COMPREHENSIVE ICD-9-CM CASEFINDING LIST
FOR REPORTABLE TUMORS (Effective Date: 10/1/2006)
COMPREHENSIVE ICD-9-CM CASEFINDING LIST
FOR REPORTABLE TUMORS (Effective Date: 10/1/2006)
140.0 – 208.9 Malignant neoplasms
225.0 – 225.9 Benign neoplasm of brain and spinal cord neoplasm
227.3 – 227.4 Benign neoplasm of pituitary gland, pineal body, and other intracranial endocrine-related structures
230.0 – 234.9 Carcinoma in situ
237.0 – 237.9 Neoplasm of uncertain behavior [borderline] of endocrine glands and nervous system
238.4 Polycythemia vera (9950/3)
238.6 Solitary plasmacytoma (9731/3)
238.6 Extramedullary plasmacytoma (9734/3)
238.71* Essential thrombocythemia (9962/3)
238.72* Low grade myelodysplastic syndrome lesions (includes 9980/3, 9982/3, 9985/3)
238.73* High grade myelodysplastic syndrome lesions (includes 9983/3)
238.74* Myelodysplastic syndrome with 5q deletion (9986/3)
238.75* Myelodysplastic syndrome, unspecified (9985/3)
238.76* Myelofibrosis with myeloid metaplasia (9961/3)
238.79* Other lymphatic and hematopoietic tissues (includes 9960/3, 9961/3, 9970/1, 9931/3)
273.2 Gamma heavy chain disease (9762/3); Franklin's disease (9762/3)
273.3 Waldenstrom's macroglobulinemia (9761/3)
288.3 Hypereosinophilic syndrome (9964/3)
289.83* Myelofibrosis (NOS) (9961/3)
795.06* Papanicolaou smear of cervix with cytologic evidence of malignancy (without histologic confirmation) (positive Pap smear)
V10.0 – V10.9 Personal history of malignancy (review these for recurrences, subsequent primaries, and/or subsequent treatment)
* New code effective 10/1/2006
Effective with 10/1/2006, screening for malignancies is no longer required for the following codes:
238.7 This code is no longer in effect.
284.9 Aplastic anemia, unspecified
285.0 Sideroblastic anemia
289.89 Other specified diseases of blood and blood-forming organs
SUPPLEMENTARY ICD-9-CM CODES TO SCREEN
FOR CANCER CASES NOT IDENTIFIED BY OTHER CODES
(Effective Date: 10/1/2006)
NOTE: Cases with these codes should be screened only as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm.
042 AIDS (This is not a malignancy code; this is for AIDS itself. Coders are instructed to add codes for AIDS-associated malignancies. Screen 042 for ‘history of’ cancers that might not be coded as active cancers.)
210.0 – 229.9 Benign neoplasms (screen for incorrectly coded malignancies or reportable-by-agreement tumors)
235.0 – 236.9 Neoplasms of uncertain behavior (screen for reportable-
by-agreement tumors)
238.0 – 238.9 Neoplasms of uncertain behavior (screen for reportable-
by-agreement tumors)
239.0 – 239.9 Neoplasms of unspecified behavior (screen for incorrectly coded malignancies or reportable-by-agreement tumors)
273.9 Unspecified disorder of plasma protein metabolism (screen for potential 273.3 miscodes)
338.3 Neoplasm related pain (acute) (chronic) (new code)
Cancer associated pain Pain due to malignancy (primary) (secondary) Tumor associated pain
528.01 Mucositis due to antineoplastic therapy (new code)
790.93 Elevated prostate specific antigen [PSA]
795.8 Abnormal tumor markers (new sub-category)
Elevated tumor associated antigens [TAA]
Elevated tumor specific antigens [TSA]
Excludes: elevated prostate specific antigen [PSA] (790.93)
795.81 Elevated carcinoembryonic antigen [CEA] (new code)
795.82 Elevated cancer antigen 125 [CA 125] (new code)
795.89 Other abnormal tumor markers (new code)
E879.2 Adverse effect of radiation therapy
E930.7 Adverse effect of antineoplastic therapy
E933.1 Adverse effect of immunosuppressive drugs
V07.3 Other prophylactic chemotherapy (screen carefully for miscoded malignancies)
V07.8 Other specified prophylactic measure
V58.0 Encounter or admission for radiotherapy
V58.11 Encounter for antineoplastic chemotherapy
V58.12 Encounter for antineoplastic immunotherapy
V66.1 Convalescence following radiotherapy
V66.2 Convalescence following chemotherapy
V67.1 Radiation therapy follow-up
V67.2 Chemotherapy follow-up
V76.0 - V76.9 Special screening for malignant neoplasm
V86.0 Estrogen receptor positive status [ER+] (new code)
V86.1 Estrogen receptor negative status [ER-] (new code)
Please note:
- Prostatic Intraepithelial Neoplasia (PIN III) M-8148/2 will NOT be collected by SEER registries.
- Pilocytic/juvenile astrocytoma M-9421 which moves from /3 to /1 will CONTINUE to be collected as a /3 in SEER registries.
- Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries which move from /3 to /1 will NOT be collected as of 1/1/2001 and previous cases will continue to have to be submitted in SEER registries.
- The World Health Organization (WHO) diagnosis "B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma" is coded as 9823/3, and cross-referenced to 9670/3, malignant lymphoma, small B lymphocytic. If this WHO term is diagnosed in blood or bone marrow, code 9823/3; if diagnosed in tissue, lymph nodes or any organ in combination with blood or bone marrow, code 9670/3.
_____________________________________
* International Classification of Diseases, Ninth Revision, Clinical Modification. U.S. Dept. of Health and Human Services, Public Health Service – Health Care Finance Administration; DHHS Publication No. (PHS) 80-1260.
|
